Abstract Bacterial phospho-N-acetylmuramyl-pentapeptide translocase (translocase I: EC 2.7.8.13) is a key enzyme in peptidoglycan biosynthesis, and a known target of antibiotics. Here we report a novel nucleoside inhibitor against translocase I, A-94964, isolated from the culture broth of the strain Streptomyces sp. SANK 60404. A-94964 inhibited bacterial translocase I with IC 50 value of 1.1 m g/ml, and showed antimicrobial activities against Staphylococcus aureus and Enterococcus faecalis with MIC of 100 and 50 m g/ml, respectively. A-94964 did not show cytotoxicity against mammalian cell lines.
Introduction
The emergence of bacterial antibiotic resistance is a serious threat to the antibiotic therapy. One of the attractive strategies to overcome this problem is to find new antibacterial agents active to novel targets. Enzymes involved in the bacterial cell wall biosynthesis pathway are essential for growth, and attractive targets for new antimicrobial agents. These enzymes include the first enzyme involved in the membrane stage of peptidoglycan synthesis, phospho-N-acetylmuramylpentapeptide translocase (translocase I), that catalyzes the transfer of MurNAc-pentapetide from UDP-MurNAcpentapetide to the lipid carrier undecaprenyl phosphate to form lipid I. There are several known translocase I inhibitors [1] , such as mureidomycins [2] , pacidamycins [3] , napsamycins [4] , liposidomycins [5] , tunicamycin [6] , capuramycins [7ϳ13], muraymycins [14] and caprazamycins [15, 16] . They exhibit antimicrobial activity against various strains including multidrug-resistant ones, and show bactericidal activity [15, 17, 18] . Thus translocase I has been an established target for the search of novel antibiotics.
In the course of our screening for bacterial translocase I inhibitors, we found inhibitory activity in the culture broth of Streptomyces sp. SANK 60404. The strain produced a novel nucleoside antibiotic with a phosphoric ester designated as A-94964 (Fig. 1) . In this report, we describe A-94964, a Novel Inhibitor of Bacterial Translocase I, Produced by Streptomyces sp. SANK 60404 the taxonomy and fermentation of the producing microorganism, as well as isolation and biological activities of A-94964.
Materials and Methods

Materials
Undecaprenyl phosphate was purchased from Larodan Fine Chemicals. Preparation methods for translocase I and a
was previously reported [10] . Tunicamycin was purchased from Sigma.
Taxonomy of the Producing Organism
The producing organism, strain SANK 60404, was isolated from a soil sample collected in Okinawa, Japan. The methods and media described by the International Streptomyces Project (ISP) [19] and Waksman [20] were used to determine the morphological characterizations and the physiological properties of the producing organism. The cell walls and whole-cell hydrolysates were analyzed by the methods of Hasegawa et al. [21] . The 16S rDNA was amplified by the polymerase chain reaction using genomic DNA of the strain and sequenced. The most related sequences were searched using the BLAST algorithm in the National Center for Biotechnology Information (NCBI). Phylogenetic analysis of the 16S rDNA sequences was performed according to the method of Nakagawa and Kawasaki [22] . A phylogenetic tree was constructed using the neighbor-joining methods [23] in MEGA, version 4.0 [24] .
Fermentation of Strain SANK 60404
A loopful amount of a culture of strain SANK 60404 was inoculated into each of three 500-ml Erlenmeyer flasks containing 80 ml of sterilized seed medium consisting of glucose 1 and CB-442 (NOF Co., Ltd.) 0.005%, pH 7.0. The inoculated flasks were incubated on a rotary shaker (210 rpm) at 28°C for 3 days. Then 2.0 ml aliquots of the culture were transferred into each of twenty-six 500-ml Erlenmeyer flasks containing 80 ml of sterilized production medium with the same composition as that of the seed medium. The inoculated flasks were incubated on a rotary shaker (210 rpm) at 28°C for 7 days.
Measurement of Translocase I Inhibitory Activity
The measurement of translocase I inhibitory activity was carried out in 96-well microtitre polystyrene plates consisting of the following: 100 ml containing 100 mM Tris-HCl (pH 7.5), 50 mM KCl, 25 mM MgCl 2 , 0.8% Triton X-100, 166 mM undecaprenyl phosphate, and
The reaction was initiated by the addition of enzyme (0.625ϳ 2.5 m g protein). The enzyme activity was monitored by measuring the increase in fluorescence at 538 nm (excitation at 355 nm).
Antimicrobial Activities
MICs were determined by the agar dilution method using Mueller Hinton agar (Becton Dickinson and Company).
Cell Culture
HeLa (cervix adenocarcinoma) and A549 (lung adenocarcinoma) were cultured in DMEM supplemented with 10% FBS.
Assay of Cytotoxicity
The cytotoxicity was determined by measuring the reduction product of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) [25] . In brief, HeLa and A549 were seeded at 5ϫ10 3 cells/well in 96-well microplates and cultured overnight. The cells were treated with various concentrations of A-94964 and tunicamycin for 72 hours. Growth was measured by formazan formation (detected at 570 nm) after treatment of the cells with 0.5 mg/ml of MTT for 4 hours at 37°C. IC 50 values were determined from the dose-response curves of growth inhibition.
General Experimental Procedures
Fluorescence was measured at room temperature on a fluorescence spectrophotometer, Fluoroskan Ascent (Labsystems).
Results
Taxonomy
Strain SANK 60404 formed straight to flexuous spore chains. Most spores were oblong and 0.4ϳ0.7ϫ0.8ϳ 1.2 mm in size with smooth surface (Fig. 2) . The cultural characteristics of the various agar media at 28°C for 14 days are presented in Table 1 . The physiological properties of the strain and the type of carbon source utilized are summarized in Table 2 . The vegetative mycelium was pale None yellowish brown to yellowish gray. The whole-cell hydrolysates of the strain contained LLdiaminopimelic acid. An almost complete 16S rDNA sequence (1447 bp) was determined so as to make phylogenetic tree based on 16S rDNA sequences of strain SANK 60404 and the genus Streptomyces including other producing organisms of translocase I inhibitors (Fig. 3) . The highest 16S rDNA sequence similarities were found with "Streptomyces coeruleoaurantiacus" NBRC 14526 (99.8%) which is not a validly established species. Based on the taxonomic properties and the 16S rDNA gene sequence, the strain was identified as Streptomyces sp. SANK 60404. The strain SANK 60404 was deposited in the International Patent Organism Depositary, National Institute of Advanced Industrial Science and Technology, Ibaraki Prefecture, Japan with the accession number FERM BP-10112.
Isolation
The isolation procedure of A-94964 is outlined in Fig. 4 . First, the culture broth (2.0 liters) was extracted with an equal volume of acetone and was centrifuged (3,000 rpm, 10 minutes). The supernatant was concentrated to a small volume and was adjusted to pH 3.0 with 1.0 M HCl. Then the supernatant was adsorbed on a Diaion HP20 column (400 ml, Mitsubishi Chemical Corporation). The column was washed with 30% Me 2 CO (1.4 liters) and the active substance was eluted with 50% Me 2 CO (1.4 liters). The active eluate was concentrated in vacuo and lyophilized to give a crude powder (1.3 g). Then 300 mg portion of this crude powder were dissolved in 1.0 ml of 15% MeCN with 10 mM ammonium bicarbonate and adsorbed on a column of Diaion CHP20P. The column was washed with 15% MeCN (200 ml) and 20% MeCN (200 ml), and the active substances was eluted with 25% MeCN (400 ml). The active fraction was concentrated in vacuo and lyophilized to give a crude powder (64 mg). Then 50 mg portion of this crude powder as dissolved in 4.0 ml of 50% MeOH with 1.5% triethylamine phosphate (pH 3.0) and applied on a preparative HPLC, in which CAPCELL PAK C18UG120 was developed with 50% MeCN with 1.0% triethylamine phosphate (pH 3.0). The active fractions were collected, desalted with a Diaion HP20 column, and lyophilized to give a white powder of A-94964 (18.9 mg).
Biological Activities of A-94964
A-94964 inhibited translocase I with IC 50 values of 1.1 mg/ml (In this assay, tunicamycins showed IC 50 values of 5.0 m g/ml). A-94964 showed antimicrobial activities against Staphylococcus aureus and Enterococcus faecalis with MIC of 100 and 50 mg/ml, respectively (Table 3) .
Cytotoxic Activities
In in vitro cytotoxicity of A-94964 estimated by MTT assay, this compound exhibited no cytotoxic effect up to 100 mg/ml against the human cancer cell lines, HeLa and A549, while tunicamycins showed potent cytotoxicity against these cell lines (IC 50 values against HeLa and A549 were 0.075 and 0.072 mg/ml, respectively). The numbers on the branches are confidence limits (expressed as percentages) estimated from a bootstrap analysis with 1000 replicates (above 50% are indicated).
Discussion
A novel nucleoside antibiotic, A-94964 with a very unique structure containing a phosphoric acid diester, was isolated from the fermentation broth of the strain identified as Streptomyces sp. SANK 60404. A-94964 inhibited bacterial translocase I with IC 50 value of 1.1 m g/ml, and showed antimicrobial activities against Staphylococcus aureus and Enterococcus faecalis with MIC of 100 and 50 m g/ml, respectively. The partial structures of A-94964 resembled those of tunicamycins, but the linkages of these structures are different from each other. So, we examined tunicamycins for their translocase I inhibitory activity. Tunicamycins showed IC 50 values of 5.0 mg/ml, indicating that A-94964 is five times more potent. In eukaryotes, it is known that tunicamycins inhibit UDP-N-acetylglucosamine: dolichol phosphate GlcNAc-1-P transferase (GPT) that catalyzes the first step in protein glycosylation [26] and show cytotoxicity for the mammalian cells. Then, we measured cytotoxic activities of A-94964 and tunicamycins against mammalian cell lines. While tunicamycins showed potent cytotoxicity (IC 50 values against HeLa and A549 were 0.075 and 0.072 mg/ml, respectively), A-94964 showed no cytotoxicity up to 100 mg/ml against mammalian cell lines. So, it seems very likely that A-94964 do not show inhibitory activity for mammalian GPT, but a specific inhibitory activity for bacterial translocase I.
There are some compounds reported as translocase I inhibitors. Most of them are also natural products containing a nucleoside moiety and have unique spectra of antimicrobial activity. In recent reports, some synthesized analogues of pacidamycins [27] , liposidomycins [28] , capuramycin [29, 30] and caprazamycins [31, 32] showed broader spectrum and more potent antimicrobial activity.
So, it seems likely that some chemical modification of A-94964 may improve the inhibitory activity for translocase I and antimicrobial activity.
In the course of our screening for translocase I inhibitors, we identified various translocase I inhibitors containing some novel compounds from the culture broth of actinomycetes. The comparison of the taxonomic position based on 16S rDNA sequence of the strain SANK 60404 with that of other producing organisms of translocase I inhibitors indicated that strain SANK 60404 is distinct from other producing translocase I inhibitors including tunicamycin. Furthermore, it is notable that strains belonging to different species of Streptomycetes produce the same compounds. Because the partial structure of A-94964 resembles those of tunicamycins, it seems likely that strain SANK 60404 has similar biosynthetic genes with those of tunicamycins. Since biosynthetic pathway of the tunicamycins is not clear yet [33] , strain SANK 60404 may contribute to study for biosynthesis of the tunicamycins and other nucleoside antibiotics. 
Streptococcus pyogenes 12255 Ͼ100
Streptococcus pneumoniae 2132 Ͼ100
Enterococcus faecalis 10785 50
Enterococcus faecium 4288 Ͼ100
Moraxella catarrhalis 11045 Ͼ100
Escherichia coli NIHJ JC-2 Ͼ100
Klebsiella pneumoniae 806 Ͼ100
Enterobacter cloacae 963 Ͼ100
Serratia marcescens IAM 1184 Ͼ100
Haemophilus influenzae 11260 Ͼ100
Pseudomonas aeruginosa PAO1 Ͼ100
Mycobacterium smegmatis SANK 75075 Ͼ100
